Inspire Medical Systems, Inc. (NYSE:INSP) Stock Holdings Decreased by Aigen Investment Management LP

Aigen Investment Management LP cut its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 14.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,645 shares of the company’s stock after selling 432 shares during the period. Aigen Investment Management LP’s holdings in Inspire Medical Systems were worth $490,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Proficio Capital Partners LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at about $4,124,000. M&T Bank Corp boosted its holdings in shares of Inspire Medical Systems by 9.2% in the 4th quarter. M&T Bank Corp now owns 3,526 shares of the company’s stock valued at $654,000 after buying an additional 298 shares during the period. Keybank National Association OH boosted its stake in Inspire Medical Systems by 0.3% during the 4th quarter. Keybank National Association OH now owns 200,759 shares of the company’s stock valued at $37,217,000 after purchasing an additional 586 shares during the period. Cornerstone Investment Partners LLC acquired a new position in Inspire Medical Systems during the 4th quarter valued at about $200,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Inspire Medical Systems by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 296,207 shares of the company’s stock valued at $54,911,000 after purchasing an additional 15,042 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO John Rondoni sold 583 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. This represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,225 shares of company stock worth $4,806,530 in the last ninety days. 4.10% of the stock is currently owned by corporate insiders.

Inspire Medical Systems Price Performance

NYSE INSP opened at $183.34 on Friday. The company’s 50 day simple moving average is $187.08 and its 200 day simple moving average is $192.70. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The company has a market capitalization of $5.44 billion, a P/E ratio of 105.98, a PEG ratio of 2.86 and a beta of 1.48.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on INSP shares. Truist Financial reduced their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Robert W. Baird reduced their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research note on Tuesday, February 11th. KeyCorp reissued an “overweight” rating and set a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their target price for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Finally, Stifel Nicolaus reduced their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $228.82.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.